文献速递心境障碍

临床医生间抗抑郁药治疗与重性抑郁障碍结局的异质性

Heterogeneity in Antidepressant Treatment and Major Depressive Disorder Outcomes Among Clinicians.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

这项纵向队列研究利用美国马萨诸塞州东部2家大型学术医学中心和6家社区医院及其附属门诊网络的电子健康记录数据,分析了2008年至2022年间每年至少记录10次重性抑郁障碍诊断的11934名临床医生。无监督学习识别出10个基于ICD编码的临床医生聚类,不同聚类间在抗抑郁药处方模式、失访比例(27%至69%)和稳定治疗达成比例(22%至42%)上存在显著差异,且临床医生聚类与治疗结局显著相关。

要点

  • 研究识别出10个临床医生聚类,在选择性5-羟色胺再摄取抑制剂、选择性去甲肾上腺素再摄取抑制剂和三环类抗抑郁药处方比例及处方抗抑郁药种类数上存在显著变异。
  • 不同临床医生聚类间患者失访比例范围为27%至69%,稳定治疗达成比例范围为22%至42%。
  • 临床医生聚类与治疗结局显著相关,纳入聚类标识的预测效果与纳入个体编码的复杂模型相似。

核心结论

  • 治疗重性抑郁障碍的临床医生群体在处方模式和电子健康记录定义的纵向患者结局上表现出显著差异。
  • 纳入临床医生聚类标识的预测效果与纳入个体编码的复杂模型相似,提示在风险分层中考虑治疗背景的重要性。

研究设计与样本

  • 纵向队列研究,使用美国马萨诸塞州东部2家大型学术医学中心和6家社区医院及其附属门诊网络的电子健康记录数据。
  • 纳入2008年至2022年间每年至少记录10次ICD-9或ICD-10重性抑郁障碍诊断的11934名去标识化临床医生。
  • 数据分析于2023年9月至2024年1月进行。

主要发现

  • 无监督学习基于ICD编码识别出10个 distinct 临床医生聚类,对应门诊精神科以及肿瘤科、产科和初级保健。
  • 聚类间在选择性5-羟色胺再摄取抑制剂、选择性去甲肾上腺素再摄取抑制剂和三环类抗抑郁药处方比例及处方抗抑郁药种类数上存在显著变异。
  • 聚类间失访比例范围为27%至69%,稳定治疗达成比例范围为22%至42%。
  • 临床医生聚类与治疗结局显著相关。
  • 纳入聚类标识的预测效果与纳入个体编码的复杂模型相似。

关键数值与推荐

  • 处方异质性定义为占某临床医生处方75%的不同抗抑郁药种类数。
  • 主要结局包括指数处方后未返回随访的患者比例和接受稳定持续抗抑郁治疗的患者比例。
  • 失访比例在不同临床医生聚类间范围为27%至69%。
  • 稳定治疗达成比例在不同临床医生聚类间范围为22%至42%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: While abundant work has examined patient-level differences in antidepressant treatment outcomes, little is known about the extent of clinician-level differences. Understanding these differences may be important in the development of risk models, precision treatment strategies, and more efficient systems of care. OBJECTIVE: To characterize differences between outpatient clinicians in treatment selection and outcomes for their patients diagnosed with major depressive disorder across academic medical centers, community hospitals, and affiliated clinics. DESIGN, SETTING, AND PARTICIPANTS: This was a longitudinal cohort study using data derived from electronic health records at 2 large academic medical centers and 6 community hospitals, and their affiliated outpatient networks, in eastern Massachusetts. Participants were deidentified clinicians who billed at least 10 International Classification of Diseases, Ninth Revision (ICD-9) or Tenth Revision (ICD-10) diagnoses of major depressive disorder per year between 2008 and 2022. Data analysis occurred between September 2023 and January 2024. MAIN OUTCOMES AND MEASURES: Heterogeneity of prescribing, defined as the number of distinct antidepressants accounting for 75% of prescriptions by a given clinician; proportion of patients who did not return for follow-up after an index prescription; and proportion of patients receiving stable, ongoing antidepressant treatment. RESULTS: Among 11 934 clinicians treating major depressive disorder, unsupervised learning identified 10 distinct clusters on the basis of ICD codes, corresponding to outpatient psychiatry as well as oncology, obstetrics, and primary care. Between these clusters, substantial variability was identified in the proportion of selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, and tricyclic antidepressants prescribed, as well as in the number of distinct antidepressants prescribed. Variability was also detected between clinician clusters in loss to follow-up and achievement of stable treatment, with the former ranging from 27% to 69% and the latter from 22% to 42%. Clinician clusters were significantly associated with treatment outcomes. CONCLUSIONS AND RELEVANCE: Groups of clinicians treating individuals diagnosed with major depressive disorder exhibit marked differences in prescribing patterns as well as longitudinal patient outcomes defined by electronic health records. Incorporating these group identifiers yielded similar prediction to more complex models incorporating individual codes, suggesting the importance of considering treatment context in efforts at risk stratification.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Rathnam S, Hart KL, Sharma A, et al. Heterogeneity in Antidepressant Treatment and Major Depressive Disorder Outcomes Among Clinicians. JAMA Psychiatry. 2024. PMID: 38985482. doi:10.1001/jamapsychiatry.2024.1778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。